TY - JOUR
T1 - Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors
AU - Sato, Younosuke
AU - Okamoto, Isamu
AU - Kameyama, Hiroki
AU - Kudoh, Shinji
AU - Saito, Haruki
AU - Sanada, Mune
AU - Kudo, Noritaka
AU - Wakimoto, Joeji
AU - Fujino, Kosuke
AU - Ikematsu, Yuki
AU - Tanaka, Kentaro
AU - Nishikawa, Ayako
AU - Sakaguchi, Ryo
AU - Ito, Takaaki
N1 - Funding Information:
Funding: This study was partially supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (18K19480, 20H03691, and 20K16334).
Funding Information:
Acknowledgments: We thank Yuko Fukuchi and Takako Maeda for their technical assistance. This study was partially supported by a grant from the Smoking Research Foundation and by an endowment from Yuko Aihara of the Aihara Allergy and Pediatric Clinic, Yokohama, Japan.
Publisher Copyright:
© 2020 by the authors.
PY - 2020/11
Y1 - 2020/11
N2 - Small-cell lung cancer (SCLC) is an aggressive malignant cancer that is classified into four subtypes based on the expression of the following key transcription and co-transcription factors: ASCL1, NEUROD1, YAP1, and POU2F3. The protein expression levels of these key molecules may be important for the formation of SCLC characteristics in a molecular subtype-specific manner. We expect that immunohistochemistry (IHC) of these molecules may facilitate the diagnosis of the specific SCLC molecular subtype and aid in the appropriate selection of individualized treatments. We attempted IHC of the four key factors and 26 candidate SCLC target molecules selected from the gene expression omnibus datasets of 47 SCLC samples, which were grouped based on positive or negative results for the four key molecules. We examined differences in the expression levels of the candidate targets and key molecules. ASCL1 showed the highest positive rate in SCLC samples, and significant differences were observed in the expression levels of some target molecules between the ASCL1-positive and ASCL1-negative groups. Furthermore, the four key molecules were coordinately and simultaneously expressed in SCLC cells. An IHC study of ASCL1-positive samples showed many candidate SCLC target molecules, and IHC could become an essential method for determining SCLC molecular subtypes.
AB - Small-cell lung cancer (SCLC) is an aggressive malignant cancer that is classified into four subtypes based on the expression of the following key transcription and co-transcription factors: ASCL1, NEUROD1, YAP1, and POU2F3. The protein expression levels of these key molecules may be important for the formation of SCLC characteristics in a molecular subtype-specific manner. We expect that immunohistochemistry (IHC) of these molecules may facilitate the diagnosis of the specific SCLC molecular subtype and aid in the appropriate selection of individualized treatments. We attempted IHC of the four key factors and 26 candidate SCLC target molecules selected from the gene expression omnibus datasets of 47 SCLC samples, which were grouped based on positive or negative results for the four key molecules. We examined differences in the expression levels of the candidate targets and key molecules. ASCL1 showed the highest positive rate in SCLC samples, and significant differences were observed in the expression levels of some target molecules between the ASCL1-positive and ASCL1-negative groups. Furthermore, the four key molecules were coordinately and simultaneously expressed in SCLC cells. An IHC study of ASCL1-positive samples showed many candidate SCLC target molecules, and IHC could become an essential method for determining SCLC molecular subtypes.
UR - http://www.scopus.com/inward/record.url?scp=85100816830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100816830&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10110949
DO - 10.3390/diagnostics10110949
M3 - Article
AN - SCOPUS:85100816830
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 11
M1 - 949
ER -